Anti-hIL6R-To-hIgA2
-
Cat.code:
hil6rto-mab7
- Documents
ABOUT
Anti-human IL-6R antibody - Human IgA2 (low effector functions)
Anti-hIL-6R-hIgA2 is an Tocilizumab biosimilar with an IgA2 isotype. Tocilizumab, also known as TCZ, is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. Tocilizumab is FDA-approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome.
Anti-hIL-6R-hIgA2 comprises the variable region of Tocilizumab and an IgA2 constant region mediating low effector functions.
This antibody can be used with HEK-Blue™ IL-6 cells for screening and neutralization assays to block recombinant human IL-6-induced signaling (see figure).
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect™ assay
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
IL-6R, CD126
Human
Sodium phosphate buffer, glycine, saccharose, stabilizing agents
Negative (tested using EndotoxDetect™ assay)
Cellular assay, ELISA, flow cytometry, Fc interaction studies
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL6R-To-hIgA2
-
Cat code:hil6rto-mab7
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
IL-6R background
Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6 to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].
References
1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.
DOCUMENTS
Documents
Technical Data Sheet
Safety Data Sheet
Validation Data Sheet
Certificate of analysis
Need a CoA ?
